Abstract To investigate the effect in 3 years of followed up after goserelin sustained-release implants combined with laparoscopic surgery for treating infertility women with endometriosis (EMS). Methods: 200 infertility women with EMS were selected and were divided into two groups (100 cases in each group) by random number method between February 2014 and February 2017. The women in the control group were treated with laparoscopic surgery, and the women in the observation group were treated with goserelin acetate sustained-release implants combined with laparoscopic surgery. The clinical effect, the situation of pain relief, the levels of sex hormones, such as follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and the levels of serum inflammatory factors, such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), soluble intercellular adhesion factor-1 (SICAM-1), the incidences of adverse reactions and recurrence within 3 years, and pregnancy outcomes of the women were compared between the two groups. Results: The effective rate (95.0%) of the women in the observation group was significant higher than that (78.0%) of control group (P<0.05). After treatment, the scores of dysmenorrhea, dysmenorrhea, and pelvic tenderness, and serum levels of FSH, LH, E2, CRP, TNF-α, IL-6 and sICAM-1 of the women in the observation group were significant lower than those of the women in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions of the women between the two groups (P>0.05). The recurrence rate within 3 years (7.0%) of the women in the observation group was significant lower than that (22.0%) of the women in the control group, but the pregnancy rate (75.0%) of the women in the observation group was significant higher than that (50.0%) of the women in the control group (P<0.05). Conclusion: Goserelin acetate sustained-release implants combined with laparoscopic surgery for treating infertility women with EMS is effectiveness, which can maintain the estrogen levels, reduce inflammatory factors levels, improve the pregnancy outcomes, and reduce recurrence rate, and has higher safety.
|